(Q35643985)

9 August 2017

5 references

13 March 2019

22 April 2019

17 June 2019

19 July 2019

6 October 2019

An update on the pathology and clinical management of gouty arthritis (English)

1 reference

human musculoskeletal system

9 August 2017

3 references

13 March 2019

22 April 2019

17 June 2019

1 reference

6 October 2019

Emilio B Gonzalez

1

1 reference

9 August 2017

publication date

9 November 2011

1 reference

9 August 2017

1 January 2012

5 references

13 March 2019

22 April 2019

17 June 2019

19 July 2019

6 October 2019

Clinical Rheumatology

6 references

9 August 2017

13 March 2019

22 April 2019

17 June 2019

19 July 2019

6 October 2019

31

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

13-21

1 reference

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

The pathogenesis of bone erosions in gouty arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

What do I need to know about gout?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

The role of interleukin-1 and the inflammasome in gout: implications for therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

TNF-induced structural joint damage is mediated by IL-1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

A pilot study of IL-1 inhibition by anakinra in acute gout

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Gout-associated uric acid crystals activate the NALP3 inflammasome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Purine-rich foods, dairy and protein intake, and the risk of gout in men.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Molecular identification of a danger signal that alerts the immune system to dying cells

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3249158

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.

12 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Prevalence of contraindications and prescription of pharmacologic therapies for gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Anakinra's efficacy is variable in refractory gout: report of ten cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Alcohol intake and risk of incident gout in men: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

Resolution of gouty tophi after twelve weeks of pegloticase treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-011-1877-0

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22069122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10067-011-1877-0

1 reference

9 August 2017

1 reference

9 August 2017

1 reference